The preclinical pharmacology of tepotinib – a highly selective MET inhibitor with activity in tumors harboring MET alterations

MLA

Joachim Albers, et al. “The Preclinical Pharmacology of Tepotinib – a Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations.” Molecular Cancer Therapeutics, Mar. 2023. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........774202e5b0174b78a406f493ef8d53fc&authtype=sso&custid=ns315887.

APA

Joachim Albers, Manja Friese-Hamim, Anderson Clark, Oliver Schadt, Gina Walter-Bausch, Christopher Stroh, Andreas Johne, Niki Karachaliou, & Andree Blaukat. (2023). The preclinical pharmacology of tepotinib – a highly selective MET inhibitor with activity in tumors harboring MET alterations. Molecular Cancer Therapeutics.

Chicago

Joachim Albers, Manja Friese-Hamim, Anderson Clark, Oliver Schadt, Gina Walter-Bausch, Christopher Stroh, Andreas Johne, Niki Karachaliou, and Andree Blaukat. 2023. “The Preclinical Pharmacology of Tepotinib – a Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations.” Molecular Cancer Therapeutics, March. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........774202e5b0174b78a406f493ef8d53fc&authtype=sso&custid=ns315887.